Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: A phase II study

Cancer Investigation

Volumn 25, Issue 6, 2007, Pages 445-448

  Evans, Devon ^b   Miner, Thomas ^b   Iannitti, David ^b   Akerman, Paul ^b   Cruff, Dennis ^b   Maia Acuna, Christine ^b   Harrington, David ^b   Habr, Fadlo ^b   Chauhan, Bharti ^b   Berkenblit, Anna ^b   Stuart, Keith ^b   Sears, Dina ^b   Kennedy, Teresa ^b   Safran, Howard ^a  

^a MIRIAM HOSPITAL   (United States)

^b NONE

Author keywords

Capecitabine; Carboplatin; Docetaxel; Esophageal cancer; Gastric cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; HYPERSENSITIVITY; INFECTION; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 34548843674     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701358025     Document Type: Article

References (23)

1. Moiseyenko, V.M.; Ajani, J.A.; Tjulandin, S.A.; et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc. Am. Soc. Clin. Oncol. 2005 (abst. 4002).
2. Tsai, J.Y.; lannitti, D.; Berkenblit, A.; Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am. J. Clin. Oncol. 2005, 4, 329-333.
3. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; et al. New guidelines to evaluate the response to treatment for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer. Inst. 2000, 92, 205-216.
4. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
5. Ajani, J.A. Chemotherapy for gastric carcinoma: new and old options. Oncology (Huntingt) 1998, 12(10 Suppl. 7): 44-47.
6. Ajani, J.A. Standard chemotherapy for gastric carcinoma: Is it a myth? J. Clin. Oncol. 2000, 18, 4001-4003.
7. Wils, J.A.; Klein, H.O.; Wagener, D.J.; et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A stop ahead in the treatment of advanced gastric cancer-A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 1991, 9, 827-831.
8. Vanhoefer, U.; Rougier, P.; Wilke, H.; et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 2000, 18, 2648-2657.
9. Kelsen, D.D.; Atiq, O.T.; Saltz, L.; et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. 1992, 10, 541-548.
10. Webb, A.; Cunningham, D.; Scarffe, J.H.; et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 1997, 15, 261-267.
11. Miwa, M.; Ura, M.; Nishida, M.; et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 1998, 34, 1274-1281.
12. Nadella, P.; Shapiro, C.; Otterson, G.A.; et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J. Clin. Oncol. 2002, 20, 2616-2623.
13. Kurosumi, M.; Tabei, T.; Suemasu, K.; et al. Enhancement of immunohistochemical reactivity of thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol. Rep. 2000, 7, 945-948.
14. O'Shaughnessey, J.; Miles, D.; Vukelja, S.; et al. Superior survival with capecitabine plus doxetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 2002, 20, 2812-2823.
15. Burris, H. Weekly schedules of docetaxel. Semin. Oncol. 1998, 6 (Suppl. 2), 21-23.
16. Hainsworth, J.D.; Burris, H.A.; Yardley, D.A.; et al.Weekly doxetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network Phase II Trial. J. Clin. Oncol. 2001, 19, 3500-3505.
17. Scheithauer, W.; Kornek, G.V.; Raderer, M.; et al: Randomized-multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first line treatment in advanced colorectal cancer. J. Clin. Oncol. 2003, 21, 1307-1312.
18. Louvet, C.; Andre, T.; Tigaud, J.M.; et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 2002, 20, 4543-4548.
19. Dank, M.; Zaluski, J.; Barone, C.; et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc. Am. Soc. Clin. Oncol. 2005 (abstr. 4003).
20. Sumpter, K.A.A.; Harper-Wynne, C.; Cunningham, D.; et al. Randomized, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation. Proc. Am. Soc. Clin. Oncol. 2003 (abstr. 1031).
21. Sternberg, C.; Kelsen, D.; Dukeman, M.; et al. Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer. Treat. Rep. 1985, 69, 1305-1307.
22. Queisser, W.; Preusser, P.; Mross, K.B.; et al. Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of phase I/II study group of the Association for Medical. Oncology of the German Cancer Society. Onkologie 1990, 13, 190-193.
23. Mannell, A.; Winters, Z. Carboplatin in the treatment of esophageal cancer. S. Afr. Med. J. 1989, 76, 213-214.